Cancers & treatments·Regimen libraryInduction

7+3 (cytarabine + anthracycline) ± midostaurin

Checked 2026-09-09

Fit adults with newly diagnosed AML; midostaurin for FLT3-mutated disease (quizartinib for FLT3-ITD)

One cycle

every 28 days × 1-2 · about 4 weeks in total

28-day cycle × 1-2 induction, then consolidation (about 4 weeks)IntravenousOral Continuous infusion Daily oral course

Components

Drug	Dose	Route	Days
Cytarabine	100-200 mg/m² per day	IV	D1-7 (168 h infusion)
Daunorubicin 60-90 mg/m² or idarubicin 12 mg/m²	daily	IV	D1-3
Midostaurin (FLT3-mutated) Small-molecule multikinase inhibitor (FLT3)	50 mg twice daily	Oral	D8-21

Cycles

1-2 induction, then consolidation

28-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Not routine

Notes

Gemtuzumab ozogamicin 3 mg/m² on days 1, 4 and 7 is added for favourable-risk CD33-positive AML (ALFA-0701).

Used in

Acute myeloid leukaemia

Trials

RATIFY (CALGB 10603)QuANTUM-First

Products

Cytarabine + anthracycline ('7+3')QuizartinibMidostaurin

Source

RATIFY, NEJM 2017; NCCN Acute Myeloid Leukemia

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Venetoclax + azacitidine

Newly diagnosed AML unfit for intensive chemotherapy

every 28 days

ATRA + arsenic trioxide

Low or intermediate-risk acute promyelocytic leukaemia (WBC 10 × 10⁹/L or less)

every 28 days

ADE (cytarabine, daunorubicin, etoposide)

Induction for younger adults with acute myeloid leukaemia in the UK MRC and NCRI trials; an alternative to 7+3

every 28 days × 2

All regimens Venetoclax + azacitidine →